Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
293,061,432
-
Total 13F shares
-
127,877,513
-
Share change
-
+6,098,494
-
Total reported value
-
$1,296,042,864
-
Put/Call ratio
-
52%
-
Price per share
-
$10.13
-
Number of holders
-
195
-
Value change
-
+$62,055,224
-
Number of buys
-
105
-
Number of sells
-
73
Institutional Holders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) as of Q4 2022
As of 31 Dec 2022,
AbCellera Biologics Inc. - Ordinary Shares (ABCL) was held by
195 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
127,877,513 shares.
The largest 10 holders included
BAILLIE GIFFORD & CO, BlackRock Inc., Voya Investment Management LLC, Voya Investment Management LLC, BAKER BROS. ADVISORS LP, Capital World Investors, ORBIMED ADVISORS LLC, HARVARD MANAGEMENT CO INC, CREDIT SUISSE AG/, and Founders Fund VII Management, LLC.
This page lists
198
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.